ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Norepinephrine Levels and Sympathetic Nervous System Activity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00001329
Recruitment Status : Completed
First Posted : November 4, 1999
Last Update Posted : March 4, 2008
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)

November 3, 1999
November 4, 1999
March 4, 2008
September 1992
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00001329 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of Norepinephrine Levels and Sympathetic Nervous System Activity
Plasma Catecholamine Kinetics

Brain and nerve cells communicate with each other by releasing and picking up chemicals called neurotransmitters. Norepinephrine is a neurotransmitter used by part of the nervous system activated during stress called the sympathetic nervous system. The sympathetic nervous system is involved with regulating blood pressure and pulse rate. Researchers believe the level norepinephrine in the blood can be used to measure activity of the sympathetic nervous system.

This study is designed to answer important questions about rates of release of norepinephrine into the blood stream, removal of released norepinephrine, and the sympathetic nervous system response to stress.

Researchers will attempt to measure levels of norepinephrine and activity of the sympathetic nervous system in patients with high blood pressure, normal patients with family histories of high blood pressure, patients taking drugs that can effect levels of norepinephrine, and patients with diseases or conditions directly affecting the sympathetic nervous system.

In order to examine sympathetic nervous system function in neurocardiological disorders and catecholaminergic effects of dietary manipulations or neuropsychiatric drugs, the protocol calls for evaluations of the kinetics of 3H-norepinephrine or 3H-epinephrine in patients with hypertension, dysautonomias, or disorders thought to involve abnormal catecholaminergic function, and in normotensive normal volunteers. Apparent spillover and clearance rates are estimated based on the norepinephrine or epinephrine concentration during the infusion and their steady-state specific activities, under resting conditions and in response to physiological or pharmacological manipulations thought to affect sympathetic outflows.
Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
  • Autonomic Nervous System Disease
  • Healthy
  • Hypertension
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
Same as current
September 2002
Not Provided

Must be greater than or equal to 18 years of age.

Must not be pregnant or lactating.

Sexes Eligible for Study: All
Child, Adult, Older Adult
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00001329
920259
92-N-0259
Not Provided
Not Provided
Not Provided
Not Provided
National Institute of Neurological Disorders and Stroke (NINDS)
Not Provided
Not Provided
National Institutes of Health Clinical Center (CC)
September 2002